Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Summary

This is an open label multi-center program to allow patients in the US with IPF access to treatment with pirfenidone.

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Lancaster L, Morrison L, Auais A, Ding B, Iqbal A, Polman B, Flaherty KR. Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program. Pulm Ther. 2017 Dec;3(2):317-325. doi: 10.1007/s41030-017-0049-z. Epub 2017 Sep 6.

Drugs

Indications